SCHEMBL16632509

SCHEMBL16632509

Oc1cc(Cl)cc2cc(Cl)ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.52
ALDH1A1 P00352 4/20 0.52
TSHR P16473 3/20 0.52
CYP3A4 P08684 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
HPGD P15428 5/20 0.43
ALOX15 P16050 3/20 0.43
ALOX12 P18054 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MAPK1 P28482 1/20 0.43
HSP90AA1 P07900 4/20 0.42
HIF1A Q16665 3/20 0.41
MEN1 O00255 2/20 0.41
HTT P42858 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
HSPA5 P11021 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079854 0.86 NQO2 (0.54) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL22275435 0.86 NQO2 (0.54) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL15093731 0.83 HSD17B10 (0.40) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL11056667 0.83 HSD17B10 (0.45) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL4960110 0.79 NQO2 (0.61) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL15600490 0.79 TRPM4 (0.63) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL12193501 0.78 SLC6A2 (0.54) HSD17B10ALDH1A1TSHRTDP1HPGD
SCHEMBL16632677 0.78 CA2 (0.42) TSHRHTTKMT2ALMNAMAPT
SCHEMBL6348188 0.77 HSD17B10 (0.43) HSD17B10ALDH1A1TSHRCYP3A4TDP1
SCHEMBL11578404 0.77 HSD17B10 (0.48) HSD17B10ALDH1A1TSHRCYP3A4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR HSD17B10 750/4885ALDH1A1 1200/4885TSHR 4583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.